[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,57,80,115,137,158,182,207,238,262],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100120158","collecting-medical-information-and-tissue-samples-from-patients-with-pancreatic-cancer-or-other-pancreatic-disorders-100120158",false,"NCT00830557","Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders","Biospecimen Resource for Pancreas Disease, a Data & Tissue Bank (Also Known as a Bio-repository, Bio-bank, Data & Tissue Database, Data & Tissue Registry, Etc.) to Help Advance Research in Pancreas Disease","* Known or suspected pancreas disease including:\n\n  * pancreas adenocarcinoma\n  * islet cell cancer\n  * pancreatic cysts\n  * pancreatitis (hereditary, acute, or chronic)\n* Next of kin of deceased participant who did not complete participation before passing away\n\nExclusion Criteria:\n\n* Under the age of 18\n* Unable to provide informed consent\n* Prison inmates","ALL","18 Years",{"count":19,"type":20},20000,"ESTIMATED","1 Year","OBSERVATIONAL","RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic disorders in the future.\n\nPURPOSE: This clinical trial is collecting medical information and tissue samples from patients with pancreatic cancer or other pancreatic disorders.",[25,26,27,28,29,30,31,32],"Islet Cell Tumor","Pancreatic Cancer","Pancreatic Disease","Acute Pancreatitis","Chronic Pancreatitis","Hereditary Pancreatitis","Pancreatic Neuroendocrine Carcinoma","Pancreatic Adenocarcinoma",[34,35,36,37,38,39,40,41,42,43],"recurrent pancreatic cancer","stage I pancreatic cancer","stage II pancreatic cancer","stage III pancreatic cancer","stage IV pancreatic cancer","recurrent islet cell carcinoma","pancreatic alpha cell carcinoma","pancreatic beta islet cell carcinoma","pancreatic delta cell carcinoma","pancreatic G-cell carcinoma","RECRUITING","2026-03-05",{"date":47,"type":48},"2026-03-09","ACTUAL",{"date":50,"type":48},"2000-10-01",{"date":52,"type":20},"2027-08-30",{"name":54,"class":55},"Mayo Clinic","OTHER",3,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100475706","the-effects-of-the-cf-carrier-state-on-the-kidneys-and-pancreas-100475706","NCT05474417","The Effects of the CF Carrier State on the Kidneys and Pancreas","CF Carrier Inclusion Criteria:\n\n* A CF Carrier identified via genetic testing\n\nControl Inclusion Criteria:\n\n* No previous CF carrier test results\n\nExclusion Criteria:\n\n* CF patient status\n* Unable to speak English\n* Currently pregnant\n* Unable to provide written informed consent\n* Prisoner status\n* Currently taking any medications for the treatment of diabetes","100 Years",{"count":65,"type":20},1250,"The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one visit where they will answer survey questions and undergo laboratory testing. Additionally, they will collect urine and stool samples at home that will be sent to outside laboratories for testing.",[68,27,69],"Carrier State","Kidney Diseases","2026-01-05",{"date":72,"type":48},"2026-01-07",{"date":74,"type":48},"2021-12-20",{"date":76,"type":20},"2026-07",{"name":78,"class":55},"Philip Polgreen",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":17,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":101,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":79},"100594803","phase-4-comparison-of-the-effectiveness-of-paracetamol-with-ibuprofen-or-paracetamol-with-metamizole-in-treating-pain-in-acute-pancreatitis-in-children-100594803","NCT07024199","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children: a Randomized Trial","Inclusion Criteria:\n\n* diagnosis of AP according to the INSPPIRE mentioned above criteria,\n* age from 3 to 18 years of age,\n* abdominal pain on admission assessed on the Numerical Rating Scale (NRS) or FLACC \\>= 4 points,\n* no analgesic treatment before enrolment in the study OR the last dose of analgesic drug (paracetamol, ibuprofen, metamizole) taken ≥ 6 hours before enrolment for examination,\n* consent of legal guardians and the child (in the case of patients ≥16 years of age) to participate in the study.\n\nExclusion Criteria - patients:\n\n* who took the last dose of painkiller (paracetamol, ibuprofen, metamizole) \\\u003C 6 hours before entering the study,\n* allergic to acetylsalicylic acid, other NSAIDs, paracetamol, metamizole,\n* with inflammatory bowel disease,\n* with gastrointestinal bleeding and other active bleeding,\n* with gastric and\u002For duodenal ulcer disease,\n* chronically taking paracetamol, NSAIDs, metamizole,\n* with liver failure,\n* with heart failure according to the NYHA II-IV scale,\n* with acute and chronic renal failure,\n* with cancer,\n* whose legal guardians did not consent to participate in the study,\n* who did not consent to participate in the study (applies to patients \\> 16 years of age).","3 Years",{"count":89,"type":20},78,"INTERVENTIONAL",[92],"PHASE4","The aim of the study is to assess the effectiveness and tolerance of pain treatment in AP in children using intravenous paracetamol in combination with ibuprofen or paracetamol in combination with metamizole. The study is prospective, interventional, and randomized.",[95,96,27,97,98,99,100],"Pancreatitis, Acute","Pain, Acute","Pancreatic Diseases","Gastroenterology","Pancreatitis","Paediatrics",[102,103,104,105],"acute pancreatitis","acute pain","painkillers","pancreatitis","2025-08-18",{"date":108,"type":48},"2025-08-24",{"date":110,"type":20},"2025-09",{"date":112,"type":20},"2027-06-01",{"name":114,"class":55},"Medical University of Warsaw",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":79},"100558512","activation-of-biobank-registry-for-bilio-pancreatic-diseases-100558512","NCT06552078","Activation of Biobank Registry for Bilio-pancreatic Diseases","Activation of Biobank for Association Study Between Environmental and Genetic Factors in Inflammatory, Functional and Neoplastic Bilio-pancreatic Diseases","BIO-PANCREAS","Inclusion Criteria:\n\n* age \\>= 18 years\n* signed informed consent\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* unwilling to sign informed consent",{"count":124,"type":20},2000,"The purpose of establishing the biobank is to create a collection of biological material and clinical data, with a prospective and retrospective mold, in order to investigate the role of genetic predisposition in multifactorial bilio-pancreatic diseases, so that an evaluation of the possible association in the pathogenesis of exogenous factors with endogenous factors can be allowed.\n\nMultifactorial diseases are in fact an expression of genetic predisposition upon which one or more environmental stimuli act. Usually the aforementioned factors are not capable individually of triggering disease but, when simultaneously present, can cause the pathological phenotype. Therefore, it becomes important in the description of disease pathogenesis to identify as many risk factors for disease prevention and early diagnosis.",[99,27,127,32],"Non-Neoplastic Pancreatic Disorder","2025-04-30",{"date":130,"type":48},"2025-05-02",{"date":132,"type":48},"2021-06-09",{"date":134,"type":20},"2030-12-31",{"name":136,"class":55},"IRCCS San Raffaele",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100579485","endoscopic-ultrasound-guided-fine-needle-aspiration-of-solid-pancreatic-lesions-with-rapid-staining-of-cytological-smears-followed-by-whole-slide-scanning-and-artificial-intelligence-diagnosis-a-prospective-multicenter-study-100579485","NCT06824909","Endoscopic Ultrasound-guided Fine-needle Aspiration of Solid Pancreatic Lesions With Rapid Staining of Cytological Smears Followed by Whole Slide Scanning and Artificial Intelligence Diagnosis: A Prospective, Multicenter Study.","内镜超声穿刺胰腺实性占位细胞涂片快速染色后全玻片扫描及人工智能诊断：一项前瞻性、多中心研究","Inclusion Criteria:\n\n* A dated and signed informed consent form A commitment to abide by the research procedures and cooperate throughout the entire study Subjects aged 18 and above, regardless of gender Diagnosis or suspicion of a solid pancreatic space-occupying lesion based on imaging studies (B-mode ultrasound, CT, or MRI)\n\nExclusion Criteria:\n\n* Unable or refusing to sign the informed consent form Unable to suspend anticoagulation\u002Fantiplatelet therapy Pregnant or lactating Having a mental illness or other medical conditions that are unsuitable for undergoing FNA\u002FB biopsy Presence of coagulation disorders (PLT \\\u003C 50 × 10\\^3\u002Fμl, INR \\> 1.5) Pancreatic cystic lesions Non-diagnostic EUS-FNA\u002FB specimens Having less than 8 microscopic fields of interest (ROI) in the digital pathology images of the entire Diff-Quik smear slide",{"count":145,"type":20},1500,"The objective of this observational study is to investigate whether the self-developed whole slide scanning and artificial intelligence diagnostic system for pancreatic solid lesion puncture cytopathology (hereinafter referred to as the \"Zhiying Shunxi\" ROSE-AI diagnostic system) can promptly and accurately diagnose solid pancreatic lesions (SPLs). The main question it aims to answer is:\n\nBy utilizing optical imaging technology to capture RGB images of Diff-Quik stained smears from pancreatic punctures, can the development of artificial intelligence algorithms assist in differentiating solid pancreatic space-occupying diseases (such as pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumors, and non-neoplastic benign lesions)?\n\nResearchers will compare the diagnoses of SPLs made by the ROSE-AI system with the actual pathological diagnoses of the SPLs themselves to determine whether the ROSE-AI system can effectively diagnose SPLs.",[27],"2025-02-08",{"date":150,"type":48},"2025-02-13",{"date":152,"type":48},"2024-12-31",{"date":154,"type":20},"2027-06-30",{"name":156,"class":55},"Ruijin Hospital",2,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":165,"sex":16,"minAge":17,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":90,"phases":169,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":79},"100500131","clinical-research-on-a-novel-deep-learning-based-system-in-pancreatic-endoscopic-ultrasound-scanning-100500131","NCT05792267","Clinical Research on a Novel Deep-learning Based System in Pancreatic Endoscopic Ultrasound Scanning","Clinical Research on Navigation and Quality Control System of Pancreatic Ultrasound Endoscopy Based on Deep Learning","Inclusion Criteria:\n\n* 1\\. Age ≥18 years old, \\\u003C80 years old 2.Patients who need endoscopic ultrasonography of pancreas; 3. Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Subjects who meet any of the following criteria cannot be selected for this trial:\n\nFirst. The patient's physical condition does not meet the requirements of conventional endoscopic ultrasonography:\n\n1. Poor physical condition, including hemoglobin ≤8.0g\u002Fdl, severe cardiopulmonary insufficiency, etc.\n2. Anesthesia assessment failed\n3. Pregnancy or breastfeeding\n4. In the acute stage of chemical and corrosive injury, it is very easy to cause perforation\n5. Recent acute coronary syndrome or clinically unstable ischemic heart attack\n6. Heart disease patients with right-to-left shunt, patients with severe pulmonary hypertension (pulmonary artery pressure\\> 90mmHg),patients with uncontrolled systemic hypertension and patients with adult respiratory distress syndrome.\n\nSecond. Disagree to participate in this study.\n\nThird. There are other problems that do not meet the requirements of this research or that affect the results of the research:\n\n1. Pancreatic disease has undergone surgery or radiotherapy and chemotherapy beforehand;\n2. Mental illness, drug addiction, inability to express themselves or other diseases that may affect follow-up.",true,"80 Years",{"count":168,"type":20},200,[170],"NA","The goal of this clinical trial is to develop and verify the auxiliary role of the artificial intelligence system in pancreatic ultrasound endoscopic scanning.The main questions it aims to answer are as follows: 1.The comparison of the image recognition accuracy between the artificial intelligence system and the ultrasound endoscopist; 2. Whether the artificial intelligence system can improve the efficiency of the pancreatic scanning for the ultrasound endoscopist. Participants will undergo pancreatic EUS with or without the assistance of the artificial intelligence system.",[27],"2025-02-07",{"date":175,"type":48},"2025-02-12",{"date":177,"type":48},"2021-01-01",{"date":179,"type":20},"2025-06-30",{"name":181,"class":55},"The Third Xiangya Hospital of Central South University",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":79},"100574811","assessing-pancreatic-fistula-rates-after-distal-pancreatectomy-using-aeon-endostapler-100574811","NCT06764134","Assessing Pancreatic Fistula Rates After Distal Pancreatectomy Using AEON Endostapler","Study Protocol for an Investigator Initiated, Observational Prospective Study, Evaluating the Rate of Postoperative Pancreatic Fistula in Distal Pancreatectomy Using AEON™ Endostapler","AEON-DP","Inclusion Criteria:\n\n* Age 18 years or older.\n* Ability to understand the nature and consequences of the study.\n* Provision of written informed consent.\n* Scheduled for minimally invasive or open distal pancreatectomy (DP) for any indication, with or without splenectomy and\u002For left adrenalectomy.\n\nExclusion Criteria:\n\n* Inability to comply with study procedures or follow-up.\n* Multivisceral resection beyond left adrenalectomy.\n* History of previous pancreatic surgeries.\n* Expected lack of compliance with the study protocol.\n* Participation in another trial that may interfere with the intervention or outcomes of this study.",{"count":191,"type":20},110,"This prospective, observational study evaluates the rate of postoperative pancreatic fistula (POPF) following distal pancreatectomy (DP) using the AEON™ Endostapler. The study involves 110 patients undergoing DP and assesses primary outcomes based on the International Study Group of Pancreatic Fistula (ISGPF) classification, alongside secondary perioperative parameters. The findings aim to optimize surgical techniques, reduce complications, and improve healthcare outcomes.",[194,195,27,196,197],"Pancreas; Fistula","Pancreas Cancer","Surgery-Complications","Surgery","2025-01-02",{"date":200,"type":48},"2025-01-08",{"date":202,"type":48},"2024-11-01",{"date":204,"type":20},"2025-10-31",{"name":206,"class":55},"University Hospital Heidelberg",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":63,"enrollmentInfo":214,"targetDuration":4,"studyType":90,"phases":216,"briefSummary":217,"conditions":218,"keywords":226,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":234,"leadSponsor":236,"locationsCount":79},"100542265","eus-examination-using-endosound-vision-system-vs-standard-echoendoscope-100542265","NCT06340620","EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope","Randomized Trial of Endoscopic Ultrasound Examination Using EndoSound Vision System vs. Standard Echoendoscope","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Any patient undergoing EUS examination for evaluation of the pancreas, bile duct, mediastinal or intraabdominal lymph nodes, or luminal lesions in the esophagus, stomach, duodenum or colon.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Unable to obtain consent for the procedure from either the patient or LAR.\n* Intrauterine pregnancy.",{"count":215,"type":20},140,[170],"This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.",[27,26,219,220,221,222,223,224,225],"Pancreatic Cyst","Gastrointestinal Tumor","Bile Duct Diseases","Bile Duct Cancer","Lymph Node Disease","Submucosal Tumor of Gastrointestinal Tract","Gastrointestinal Cancer",[227,228,229],"Endoscopic ultrasound","EndoSound Vision System","Randomized trial","2024-03-25",{"date":232,"type":48},"2024-04-01",{"date":230,"type":20},{"date":235,"type":20},"2027-12",{"name":237,"class":55},"Orlando Health, Inc.",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":245,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":79},"100454101","retrospective-study-on-microbial-diversity-in-paraffin-tissue-of-pancreatic-diseases-100454101","NCT05193162","Retrospective Study on Microbial Diversity in Paraffin Tissue of Pancreatic Diseases","Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Road II, Shanghai 200025, China","Inclusion Criteria:\n\n* Age ≥ 5 years old, ≤ 85 years old;\n* After MDT discussion, routine surgery can be performed, and the postoperative pathology is clear as pancreatic cancer and other pancreatic diseases;\n* No history of antibiotics for three months before surgery, no history of yogurt containing probiotics\n* There is no serious damage to heart, liver and kidney function.\n\nExclusion Criteria:\n\n* Antibiotics or yogurt containing probiotics history in three months;\n* Patients with evidence of sensory or motor neuropathy;\n* Those who have a clear cardiovascular disease, severe associated disease or active infection, including known HIV infection;\n* Those who have a history of other cancers.","5 Years","85 Years",{"count":248,"type":20},800,"The great harm of pancreatic diseases and the unknown etiology and pathogenesis make it difficult to intervene in most early cases in time. Previous studies by scholars and applicants at home and abroad have shown that the microflora in pancreatic tissue is closely related to chronic pancreatitis and pancreatic cancer. However, the research on the mechanism of microbial diversity in pancreatic tissue and the occurrence and development of various pancreatic diseases has not been reported. Based on the previous research, this subject continues to take various pancreatic diseases as the research object based on the database of pancreatic center and pathology department of Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University, To explore the characteristics of microbial flora in pancreas in different pancreatic diseases and its mechanism of influence on disease microenvironment. Select specific microbial flora or targets in the pancreas for various pancreatic diseases, so as to provide new theoretical basis and practical guidance for the early diagnosis and treatment of pancreatic diseases.",[26,27,251],"Microbial Colonization",[253,97,251],"Pancreatic cancer","2023-06-13",{"date":256,"type":48},"2023-06-15",{"date":258,"type":48},"2019-02-01",{"date":260,"type":20},"2026-07-31",{"name":156,"class":55},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":63,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":272,"conditions":273,"keywords":291,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":305},"100435367","spanish-series-of-patients-treated-with-the-radionuclide-lutetium177-100435367","NCT04949282","Spanish Series of Patients Treated With the Radionuclide Lutetium177","SEPTRALU, Spanish Series of Patients Treated With the Radionuclide Lutetium177","SEPTRALU","Inclusion Criteria:\n\n* Written informed consent must be obtained prior to any data collection.\n* Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour\n* Aged ≥18 years.\n\nExclusion Criteria:\n\n* None",{"count":271,"type":20},5000,"This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.",[274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,27,290],"Neuroendocrine Tumors","Intestinal Neoplasms","Pancreatic Neoplasms","Stomach Neoplasms","Neuroectodermal Tumors","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms","Neoplasms, Nerve Tissue","Gastrointestinal Neoplasms","Digestive System Neoplasms","Neoplasms by Site","Endocrine Gland Neoplasms","Digestive System Diseases","Gastrointestinal Disease","Intestinal Diseases","Endocrine System Diseases",[292,293,294,295],"GEP-NET","Gastro-Entero-Pancreatic Neuroendocrine Tumour","Luthatera","Somatostatin receptor positive tumour","2022-12-22",{"date":298,"type":48},"2022-12-23",{"date":300,"type":48},"2021-05-10",{"date":302,"type":20},"2035-12-31",{"name":304,"class":55},"Sociedad Española de Medicina Nuclear e Imagen Molecular",20]